Moderna Inc. is transitioning its business strategy by prioritizing partnerships for financing and co-developing late-stage vaccine trials, including a new cancer vaccination. This change comes as the company grapples with a 45.1% drop in revenue, mainly from reduced demand for its coronavirus vaccine, prompting it to stop self-funding Phase III trials. The new risk-sharing approach aims to preserve cash and facilitate further development in mRNA technologies, while Moderna's stock has surged by 58.5% in the past six months, signaling renewed investor confidence.
“Moderna Inc · traded contracts · total contracts · 77373”
“Moderna · will continue to lead · development for mRNA-3927”
“shares of Moderna · have rallied · 58.5% · in the past six months”
“MRNA’s earnings · beat estimates in · each of the trailing four quarters”
“Moderna · is seeking · external partners · to finance and co-develop late-stage experimental vaccines”
“Moderna · is adjusting its approach to · research spending and commercialization · while still pursuing new infectious disease targets”
“Moderna · is looking for partners to support · Phase III trials”
“Moderna’s decision to stop self-funding new Phase III vaccine trials · shifts its business model toward · risk-sharing with larger partners”
“Moderna's partnership focus · lines up with · the existing narrative that Moderna is trying to broaden its mRNA pipeline”
“Sharing trial costs · may help preserve · cash and reduce funding risk · while Moderna is dealing with declining revenue from its coronavirus vaccine”
“If partnerships accelerate late-stage progress · they could support the effort to diversify · beyond COVID-related products”
“Moderna, Inc. (NASDAQ:MRNA) · is working on · a cancer vaccination · true”